Industry News
Biotechnology Industry News
Super-fit mice reveal anti-inflammatory protein that could boost search for Alzheimer’s drugs
Super-fit mice reveal anti-inflammatory protein that could boost search for Alzheimer's drugs arlene.weintraub Fri, 12/10/2021 - 08:09
Moderna, hoping to prove it’s no one-trick COVID pony, posts early peek at mRNA flu shot hopeful
Moderna, hoping to prove it's no one-trick COVID pony, posts early peek at mRNA flu shot hopeful badams Fri, 12/10/2021 - 07:57
Eli Lilly pens $1.5B biobucks pact with China’s Regor for metabolic disease work
Eli Lilly pens $1.5B biobucks pact with China's Regor for metabolic disease work badams Fri, 12/10/2021 - 06:49
Roche posts ‘impressive’ TIGIT combo lung cancer data, but trial deaths weigh down shares
Roche posts 'impressive' TIGIT combo lung cancer data, but trial deaths weigh down shares badams Fri, 12/10/2021 - 05:28
Novartis poaches Roche’s neuro and rare disease R&D lead, replacing Shanker
Novartis poaches Roche's neuro and rare disease R&D lead, replacing Shanker badams Fri, 12/10/2021 - 04:34
Albireo CMO Horn is out the door 5 months after US, EU approvals of rare liver disease drug
Albireo CMO Horn is out the door 5 months after US, EU approvals of rare liver disease drug klahucik Thu, 12/09/2021 - 14:02
Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments
Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments klahucik Thu, 12/09/2021 - 12:34
Biopharma charts progress in translating CAR-T cell therapies to solid cancers
Biopharma charts progress in translating CAR-T cell therapies to solid cancers arlene.weintraub Thu, 12/09/2021 - 10:20
ASH: 2 years in, the survival data on J&J’s rival to Bristol Myers’ BCMA cell therapy are still growing
ASH: 2 years in, the survival data on J&J's rival to Bristol Myers' BCMA cell therapy are still growing ntaylor Thu, 12/09/2021 - 09:25
ASH: Novartis posts early clinical data on next-gen CAR-Ts, sets sights on 2022 registration trials
ASH: Novartis posts early clinical data on next-gen CAR-Ts, sets sights on 2022 registration trials ntaylor Thu, 12/09/2021 - 09:18
K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis
K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis klahucik Thu, 12/09/2021 - 08:31
Totus tots up $40M in series A funding to go after competitive cancer space
Totus tots up $40M in series A funding to go after competitive cancer space ntaylor Thu, 12/09/2021 - 08:15
ASH: Senti Bio’s gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models
ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models aliu Thu, 12/09/2021 - 07:40
Novartis works on pan-coronavirus pill, eyes 2022 human testing
Novartis works on pan-coronavirus pill, eyes 2022 human testing badams Thu, 12/09/2021 - 04:34
Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scene
Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scene ntaylor Wed, 12/08/2021 - 10:50
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial ntaylor Wed, 12/08/2021 - 08:38
Merck KGaA steps up VC activity with $677M investment, positioning M Ventures to keep pace with changing landscape
Merck KGaA steps up VC activity with $677M investment, positioning M Ventures to keep pace with changing landscape ntaylor Wed, 12/08/2021 - 03:52
J&J squares up to Big Pharma rivals with extra RSV vaccine data
J&J squares up to Big Pharma rivals with extra RSV vaccine data ntaylor Tue, 12/07/2021 - 08:01
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategy
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategy ntaylor Tue, 12/07/2021 - 05:44
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy ntaylor Tue, 12/07/2021 - 05:44